{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:28:11Z","timestamp":1790483291615,"version":"4.1.0"},"reference-count":76,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,7,12]],"date-time":"2012-07-12T00:00:00Z","timestamp":1342051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To investigate the impact of scaling\u2010up opiate substitution therapy (<jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content>) and high coverage needle and syringe programmes (100%<jats:styled-content style=\"fixed-case\">NSP<\/jats:styled-content>\u2014obtaining more sterile syringes than you inject) on <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> prevalence among injecting drug users (<jats:styled-content style=\"fixed-case\">IDU<\/jats:styled-content>s).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> virus <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> transmission modelling using <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content> estimates for effect of <jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content> and 100%<jats:styled-content style=\"fixed-case\">NSP<\/jats:styled-content> on individual risk of <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Range of chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> prevalent (20\/40\/60%) settings with no <jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content>\/100%<jats:styled-content style=\"fixed-case\">NSP<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content> setting with 50% coverage of both <jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content> and 100%<jats:styled-content style=\"fixed-case\">NSP<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Injecting drug users.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>Decrease in <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> prevalence after 5\u201320 years due to scale\u2010up of <jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content> and 100%<jats:styled-content style=\"fixed-case\">NSP<\/jats:styled-content> to 20\/40\/60% coverage in no <jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content>\/100%<jats:styled-content style=\"fixed-case\">NSP<\/jats:styled-content> settings, or from 50% to 60\/70\/80% coverage in the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content> setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>For 40% chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> prevalence, scaling\u2010up <jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content> and 100%<jats:styled-content style=\"fixed-case\">NSP<\/jats:styled-content> from 0% to 20% coverage reduces <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> prevalence by 13% after 10 years. This increases to a 24\/33% relative reduction at 40\/60% coverage. Marginally less impact occurs in higher prevalence settings over 10 years, but this becomes more pronounced over time. In the United Kingdom, without current coverage levels of <jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content> and 100%<jats:styled-content style=\"fixed-case\">NSP<\/jats:styled-content> the chronic <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> prevalence could be 65% instead of 40%. However, increasing <jats:styled-content style=\"fixed-case\">OST<\/jats:styled-content> and 100%<jats:styled-content style=\"fixed-case\">NSP<\/jats:styled-content> coverage further is unlikely to reduce chronic prevalence to less than 30% over 10 years unless coverage becomes \u226580%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Scaling\u2010up opiate substitution therapy and high coverage needle and syringe programmes can reduce hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> prevalence among injecting drug users, but reductions can be modest and require long\u2010term sustained intervention coverage. In high coverage settings, other interventions are needed to further decrease hepatitis <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content> prevalence. In low coverage settings, sustained scale\u2010up of both interventions is needed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1360-0443.2012.03932.x","type":"journal-article","created":{"date-parts":[[2012,5,7]],"date-time":"2012-05-07T12:43:37Z","timestamp":1336394617000},"page":"1984-1995","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis <scp>C<\/scp> virus prevalence? Model projections for different epidemic settings"],"prefix":"10.1111","volume":"107","author":[{"given":"Peter","family":"Vickerman","sequence":"first","affiliation":[{"name":"London School of Hygiene and Tropical Medicine  London UK"},{"name":"University of Bristol  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Martin","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine  London UK"},{"name":"University of Bristol  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Turner","sequence":"additional","affiliation":[{"name":"University of Bristol  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[{"name":"University of Bristol  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.013"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199802001-00003"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70216-4"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02759.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61097-0"},{"key":"e_1_2_6_7_1","volume-title":"The Primary Prevention of Hepatitis C among Infecting Drug Users","author":"Advisory Council on Misuse of Drugs","year":"2009"},{"key":"e_1_2_6_8_1","volume-title":"Preventing HIV Infection among Injecting Drug Users in High\u2010Risk Countries: An Assessment of the Evidence","author":"Tilson H.","year":"2007"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02888.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199910010-00002"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.01912.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir196"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03515.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-006-9089-7"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000192066.86410.8c"},{"key":"e_1_2_6_16_1","unstructured":"National Centre in HIV Epidemiology and Clinical Research.Return on investment 2: Evaluating the cost\u2010effectiveness of needle and syringe programs in Australia.Sydney:National Centre in HIV Epidemiology and Clinical Research;2009."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp141"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq112"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/588297"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-008-9330-7"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2002.00128.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq111"},{"key":"e_1_2_6_23_1","volume-title":"Harm Reduction: Evidence, Impacts and Challenges","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2010"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60232-2"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280208094704"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3172"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00651.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1086\/605947"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis213"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.08.029"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.21905"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03140.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c5475"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.05.021"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2010.03.022"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1017\/S095026880900212X"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdp067"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00855.x"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22534"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08435-0"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990802342899"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268806007035"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280208094691"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.12.035"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.01.013"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1086\/649783"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.11.007"},{"issue":"3","key":"e_1_2_6_48_1","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick R. P.","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.04.003"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02249.x"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2006.12.014"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00296.x"},{"key":"e_1_2_6_53_1","first-page":"620","article-title":"The effectiveness of drug treatment programs in reducing criminal behavior: a meta\u2010analysis","volume":"18","author":"Holloway K. R.","year":"2006","journal-title":"Psicothema"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05356-2"},{"key":"e_1_2_6_55_1","unstructured":"JonesL. PickeringL. SumnallH. McVeighJ. BellisM.A review of the effectiveness and cost\u2010effectiveness of needle and syringe programmes for injecting drug users. London: National Institute for Health and Clinical Excellence.2008."},{"key":"e_1_2_6_56_1","unstructured":"VickermanP. MinersA. WilliamsJ.Assessing the cost\u2010effectiveness of interventions linked to needle and syringe programmes for injecting drug users: an economic modelling report. London: National Institute for Health and Clinical Excellence.2008."},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta11090"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyl276"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2008.034660"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyg102"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.08.017"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1997.tb02895.x"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.06.020"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.epidem.2008.10.002"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282ef7701"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268802006945"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2011.630359"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2011.608420"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.olq.0000221335.80508.fa"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02755.x"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01741.x"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540129947811"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.evalprogplan.2003.09.001"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdq088"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1151\/spp021122"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-6-42"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68804-1"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1360-0443.2012.03932.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1360-0443.2012.03932.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T16:01:23Z","timestamp":1695484883000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1360-0443.2012.03932.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,12]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1360-0443.2012.03932.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1360-0443.2012.03932.x","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,12]]},"assertion":[{"value":"2011-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-05-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}